Also known as ETB115, AMG531, SB-497115-GR, 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid
Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. It is a thrombopoietin receptor agonist. It is taken by mouth.
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 461093150 | image = eltrombopag.svg | image_class = skin-invert-image | width = 270 | alt = | caption =
| pronounce = | tradename = Promacta, Revolade, others | Drugs.com = | MedlinePlus = a609011 | DailyMedID = Eltrombopag olamine | pregnancy_AU = B3 | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = | ATC_prefix = B02 | ATC_suffix = BX05 | ATC_supplemental =
via Wikipedia infobox
via PubMed
via Wikidata sitelinks · CC0
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).